Published in Clin Cancer Res on August 11, 2010
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity (2011) 1.72
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res (2013) 1.42
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res (2012) 1.23
Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.21
Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) (2011) 1.21
Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol (2012) 1.20
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol (2013) 1.17
Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11
Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res (2012) 1.10
TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. Clin Cancer Res (2015) 1.10
The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res (2015) 1.04
Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res (2014) 1.03
Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol (2012) 1.00
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol (2012) 0.98
Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol (2011) 0.98
Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol (2011) 0.97
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PLoS One (2014) 0.96
Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Semin Cancer Biol (2012) 0.95
Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology (2013) 0.94
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother (2013) 0.94
Whole cell vaccines--past progress and future strategies. Semin Oncol (2012) 0.93
Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res (2013) 0.93
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget (2015) 0.92
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene (2013) 0.91
Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia (2014) 0.90
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res (2015) 0.90
Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget (2015) 0.88
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J (2013) 0.88
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res (2015) 0.88
α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response. Breast Cancer Res (2011) 0.87
Immunomodulatory effect of bisphosphonate risedronate sodium on CD163+ arginase 1+ M2 macrophages: the development of a possible supportive therapy for angiosarcoma. Clin Dev Immunol (2013) 0.87
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85
Cancer-Associated Myeloid Regulatory Cells. Front Immunol (2016) 0.85
Bioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling. Cancer Immunol Immunother (2014) 0.84
A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Cancer Res (2011) 0.84
Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology (2016) 0.83
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol Cancer (2014) 0.82
Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis (2015) 0.82
Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann Oncol (2013) 0.81
Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin. Sci Rep (2016) 0.80
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget (2016) 0.79
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Ann Oncol (2016) 0.79
The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. J Biomed Biotechnol (2011) 0.79
Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol (2015) 0.79
Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clin Cancer Res (2016) 0.79
Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. Front Immunol (2015) 0.79
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother (2016) 0.79
Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy. Sci Rep (2016) 0.78
Bone marrow mesenchymal stem cells suppress metastatic tumor development in mouse by modulating immune system. Stem Cell Res Ther (2015) 0.78
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol (2015) 0.78
Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) (2013) 0.78
Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol (2017) 0.77
MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. Oncotarget (2016) 0.77
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Ther Adv Med Oncol (2016) 0.77
Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy. Front Oncol (2012) 0.76
Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells. J Immunother Cancer (2014) 0.76
Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy. Oncoimmunology (2012) 0.76
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol (2015) 0.75
Identification of Caspase-6 as a New Regulator of Alternatively Activated Macrophages. J Biol Chem (2016) 0.75
Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Clin Immunol (2016) 0.75
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget (2016) 0.75
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy. Cancer Sci (2016) 0.75
Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells. Crit Rev Immunol (2016) 0.75
Jacalin-Activated Macrophages Exhibit an Antitumor Phenotype. Biomed Res Int (2016) 0.75
Targeting tumor-associated macrophages to combat pancreatic cancer. Oncotarget (2016) 0.75
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. Int J Mol Sci (2017) 0.75
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A (1980) 8.94
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 6.61
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res (2007) 4.39
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol (2008) 3.91
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res (2003) 3.45
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol (2000) 3.07
New vistas on macrophage differentiation and activation. Eur J Immunol (2007) 2.99
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother (2005) 2.87
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol (2008) 2.76
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 2.19
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer (2002) 1.71
Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol (2009) 1.68
Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res (1987) 1.59
Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene (2006) 1.40
Quantitative validation and comparison of multiplex cytokine kits. J Biomol Screen (2010) 1.40
From phagocyte diversity and activation to probiotics: back to Metchnikoff. Eur J Immunol (2008) 1.11
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother (2008) 1.05
Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther (2010) 1.00
Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Res (1994) 0.99
An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2005) 0.84
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One (2011) 2.61
Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res (2012) 2.14
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 1.83
ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene (2004) 1.56
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood (2007) 1.54
Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J Biol Chem (2002) 1.47
The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem (2008) 1.46
Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. Cancer (2010) 1.45
Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol (2004) 1.41
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 1.38
A view to a kill: signals triggering cytotoxicity. Clin Cancer Res (2002) 1.38
Emerging mechanisms of T-tubule remodelling in heart failure. Cardiovasc Res (2013) 1.35
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol (2005) 1.34
Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood (2007) 1.32
Resolution of the novel immune-type receptor gene cluster in zebrafish. Proc Natl Acad Sci U S A (2004) 1.30
An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res (2009) 1.30
IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J Immunol (2009) 1.28
Syk regulation of phosphoinositide 3-kinase-dependent NK cell function. J Immunol (2002) 1.28
Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood (2007) 1.23
A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis (2011) 1.22
Advances and challenges in basic and translational research on clusterin. Cancer Res (2009) 1.20
Cohort Profile: the Dongfeng-Tongji cohort study of retired workers. Int J Epidemiol (2012) 1.19
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood (2004) 1.18
Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest (2013) 1.15
Clusterin and chemoresistance. Adv Cancer Res (2009) 1.14
PRDM1/Blimp-1 controls effector cytokine production in human NK cells. J Immunol (2010) 1.11
Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer (2009) 1.11
Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther (2007) 1.10
A comparison of murine smooth muscle cells generated from embryonic versus induced pluripotent stem cells. Stem Cells Dev (2009) 1.09
CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies. Carcinogenesis (2010) 1.09
Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood (2004) 1.09
Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res (2007) 1.08
A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood (2008) 1.07
Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. PLoS One (2011) 1.07
Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood (2002) 1.05
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol (2011) 1.05
Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol (2011) 1.05
Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation. J Biol Chem (2011) 1.04
Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res (2003) 1.04
The zebrafish activating immune receptor Nitr9 signals via Dap12. Immunogenetics (2007) 1.02
A novel functional variant (-842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis (2009) 1.02
Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol (2011) 1.00
Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol (2005) 1.00
Regulation of Akt-dependent cell survival by Syk and Rac. Blood (2002) 1.00
Genetic variations in TERT-CLPTM1L genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis (2010) 1.00
Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther (2010) 1.00
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A (2014) 0.99
Chronic disease mortality in rural and urban residents in Hubei Province, China, 2008-2010. BMC Public Health (2013) 0.99
Application of a hybrid model for predicting the incidence of tuberculosis in Hubei, China. PLoS One (2013) 0.98
Is activation of coronary venous cells the key to cardiac regeneration? Nat Clin Pract Cardiovasc Med (2008) 0.98
Vitamin D Receptor Genetic Polymorphisms and Prostate Cancer Risk: A Meta-analysis of 36 Published Studies. Int J Clin Exp Med (2009) 0.98
Human neutrophils utilize a Rac/Cdc42-dependent MAPK pathway to direct intracellular granule mobilization toward ingested microbial pathogens. Blood (2003) 0.98
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem (2012) 0.97
Ikaros isoform x is selectively expressed in myeloid differentiation. J Immunol (2003) 0.96
Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood (2008) 0.96
[Survey on knowledge, attitude, practice related to contraception among college students in Beijing]. Zhonghua Liu Xing Bing Xue Za Zhi (2009) 0.95
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol (2011) 0.95
TERT-CLPTM1L polymorphism rs401681 contributes to cancers risk: evidence from a meta-analysis based on 29 publications. PLoS One (2012) 0.94
Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res (2012) 0.94
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res (2013) 0.92
Immune-related, lectin-like receptors are differentially expressed in the myeloid and lymphoid lineages of zebrafish. Immunogenetics (2006) 0.92
Triptolide inhibits extracellular matrix protein synthesis by suppressing the Smad2 but not the MAPK pathway in TGF-beta1-stimulated NRK-49F cells. Nephrol Dial Transplant (2010) 0.92
Association between serum uric acid and the metabolic syndrome among a middle- and old-age Chinese population. Eur J Epidemiol (2013) 0.90
Evaluating the effectiveness of an emergency preparedness training programme for public health staff in China. Public Health (2008) 0.89
In situ confocal imaging in intact heart reveals stress-induced Ca(2+) release variability in a murine catecholaminergic polymorphic ventricular tachycardia model of type 2 ryanodine receptor(R4496C+/-) mutation. Circ Arrhythm Electrophysiol (2012) 0.88
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid (2013) 0.87
Telomere length and TERT functional polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. Pharmacogenet Genomics (2011) 0.87
Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer (2008) 0.87
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A (2013) 0.87
Sleep duration and cancer risk: a systematic review and meta-analysis of prospective studies. Asian Pac J Cancer Prev (2013) 0.86
Deciphering ryanodine receptor array operation in cardiac myocytes. J Gen Physiol (2010) 0.86
Development and evaluation of a leadership training program for public health emergency response: results from a Chinese study. BMC Public Health (2008) 0.86
Urgent need for contraceptive education and services in Chinese unmarried undergraduates: a multi-campus survey. J Huazhong Univ Sci Technolog Med Sci (2011) 0.86